Cancer patients and healthy subjects often harbor a repertoire of self-reactive T cells and antibodies. This led to the idea that if one could break immunological tolerance to these self-antigens in a controllable manner one would find a "therapeuitic window" in which an autoimmune response might damage cancers more than normal tissues. This approach has worked reasonably well with chemotherapies, which, although not cancer specific, can confer clinical benefit with acceptable morbidities.
No comments:
Post a Comment